Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Articles published by Scribe Therapeutics Inc.

News headline image
Scribe Therapeutics Highlights Data Underpinning its Comprehensive Strategy Targeting Key Lipid Drivers of ASCVD at American Heart Association (AHA) Scientific Sessions 2025
From Scribe Therapeutics Inc.
Via Business Wire
News headline image
Scribe Therapeutics Highlights Latest Data on Lp(a)-Lowering Therapy and Novel AI Platform for Next-Generation CRISPR-Based Therapeutics at Two Premier Conferences
From Scribe Therapeutics Inc.
Via Business Wire
News headline image
Scribe Therapeutics Reports Positive Preclinical Data on its Novel CRISPR Technologies at the 2025 EAS Congress and ASGCT Annual Meeting
From Scribe Therapeutics Inc.
Via Business Wire
News headline image
Scribe Therapeutics to Highlight In Vivo CRISPR-based Genome Editing Data for Duchenne Muscular Dystrophy at ASGCT 2025, in Addition to Joint Presentation with Prevail Therapeutics, a Part of Lilly’s Gene Therapy Division
From Scribe Therapeutics Inc.
Via Business Wire
News headline image
Scribe Therapeutics to Unveil Latest Preclinical Data on Proprietary CRISPR Epigenetic Silencing Technology for LDL-C Lowering at the 2025 EAS Congress
From Scribe Therapeutics Inc.
Via Business Wire
News headline image
Scribe Therapeutics Presents Data on its Epigenetic Long-Term X-Repressor Technology at the 2025 Keystone Symposia on Precision Genome Engineering Conference
From Scribe Therapeutics Inc.
Via Business Wire
News headline image
Scribe Therapeutics to Participate in Upcoming Conferences
From Scribe Therapeutics Inc.
Via Business Wire
News headline image
Scribe Therapeutics Achieves Milestone for In Vivo Program in Collaboration with Sanofi
From Scribe Therapeutics Inc.
Via Business Wire
News headline image
Scribe Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Scribe Therapeutics Inc.
Via Business Wire
News headline image
Scribe Therapeutics Reports Preclinical Data Validating its CRISPR Genome Editing and Epigenome Modifying Technologies for Addressing Cardiometabolic Disease at American Heart Association (AHA) Scientific Sessions 2024
From Scribe Therapeutics Inc.
Via Business Wire
News headline image
Scribe Therapeutics to Present Preclinical Data on CRISPR Genome and Epigenome Editing Technologies at American Heart Association (AHA) Scientific Sessions 2024
From Scribe Therapeutics Inc.
Via Business Wire
News headline image
Scribe Therapeutics to Participate in Upcoming Conferences
From Scribe Therapeutics Inc.
Via Business Wire
News headline image
Scribe Therapeutics Presents Data Demonstrating Highly Potent Gene Editing In Vivo, Including Saturated Editing of Hepatocytes in NHPs, by an Engineered XE Genome Editor; Showcases Novel Epigenetic Editing Capabilities at 2024 ASGCT Annual Meeting
From Scribe Therapeutics Inc.
Via Business Wire
News headline image
Scribe Therapeutics to Present on Advances in CRISPR Genome and Epigenome Editing at the 2024 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting
From Scribe Therapeutics Inc.
Via Business Wire
News headline image
Scribe Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
From Scribe Therapeutics Inc.
Via Business Wire
News headline image
Scribe Therapeutics Expands In Vivo Collaboration with Sanofi to Second Target
From Scribe Therapeutics Inc.
Via Business Wire
News headline image
Scribe Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Scribe Therapeutics Inc.
Via Business Wire
News headline image
Scribe Therapeutics Appoints Dr. Aarif Khakoo as Chief Scientific Officer and Head of Research and Development, and Dr. Maria Mirotsou as Vice President of Discovery Biology
From Scribe Therapeutics Inc.
Via Business Wire
News headline image
Scribe Therapeutics Expands Collaboration with Sanofi to Advance In Vivo Genetic Medicines for Sickle Cell and Other Genomic Diseases
From Scribe Therapeutics Inc.
Via Business Wire
News headline image
Scribe Therapeutics Presents Data on its X-Editing Technologies at 2023 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
From Scribe Therapeutics Inc.
Via Business Wire
News headline image
Scribe Announces Collaboration with Prevail, a Wholly Owned Subsidiary of Lilly, to Accelerate In Vivo CRISPR-based Genetic Medicines for Neurological and Neuromuscular Diseases
From Scribe Therapeutics Inc.
Via Business Wire
News headline image
Scribe Therapeutics Announces Oral Presentation at 2023 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
From Scribe Therapeutics Inc.
Via Business Wire
News headline image
Scribe Therapeutics to Participate in Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Days
From Scribe Therapeutics Inc.
Via Business Wire
News headline image
Scribe Therapeutics to Participate in Four Upcoming Conferences
From Scribe Therapeutics Inc.
Via Business Wire
News headline image
Scribe Therapeutics to Participate in Upcoming Investor Conferences
From Scribe Therapeutics Inc.
Via Business Wire
News headline image
Scribe Therapeutics Announces Expansion of San Francisco Bay Area Headquarters, 3 Key Senior Hires
From Scribe Therapeutics Inc.
Via Business Wire
News headline image
Scribe Therapeutics to Participate in SVB Securities Biopharma Private Company Connect
From Scribe Therapeutics Inc.
Via Business Wire
News headline image
Scribe Therapeutics Expands Collaboration With Biogen to Second Target
From Scribe Therapeutics Inc.
Via Business Wire
News headline image
Scribe Therapeutics to Participate in Upcoming Goldman Sachs The New Guard: Privates Leading the Disruption in Healthcare Investor Conference
From Scribe Therapeutics Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.